Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients

(2010) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

(2010) R. K. Jain et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

(2010) T. Puchalski et al.   CLINICAL CANCER RESEARCH

Applying Physiological and Biochemical Concepts to Optimize Biological Drug Development

(2010) PJ Lowe   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacometrics 2020

(2010) Jogarao V. S. Gobburu   JOURNAL OF CLINICAL PHARMACOLOGY

Model-Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development

(2010) Jeffrey D. Wetherington et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

(2009) Brett E. Houk et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

(2009) Y Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

(2009) Anthe S. Zandvliet et al.   INVESTIGATIONAL NEW DRUGS

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics

(2009) Laurent Claret et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer

(2008) N M G M Appels et al.   BRITISH JOURNAL OF CANCER

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics

(2008) Balaji M. Agoram   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients

(2008) J. Li et al.   CLINICAL CANCER RESEARCH

PK/PD modelling and simulations: utility in drug development

(2008) Iris Rajman   DRUG DISCOVERY TODAY

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

(2008) Chiaki Tanaka et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose Selection in Phase I Studies: Why We Should Always Go for the Top

(2008) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacodynamic-Guided Modified Continuous Reassessment Method–Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors

(2008) Antonio Jimeno et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommended changes to oncology clinical trial design: Revolution or evolution?

(2007) Mark J. Ratain et al.   EUROPEAN JOURNAL OF CANCER